Immunosuppressive therapy and COVID ‐19 infection in patients with NMOSD
DiscussionImmunosuppressant-treated patients with NMOSD have a similar risk of COVID-19 infection as the general population, but the disease duration is shorter and the clinical symptoms are less severe. Among our NMOSD patients who received hUC-MSCs treatment, COVID-19 outcomes were favorable, with no increased risk of severe COVID-19. Prospective studies on immunotherapies are needed to help determine best treatment practices.
Source: Immunity, Inflammation and Disease - Category: Allergy & Immunology Authors: Un Wai Choi,
Xiwen Ai,
Hongyan Li,
Yong Hao,
Xiaoying Yao,
Yangtai Guan Tags: SHORT REPORT Source Type: research
More News: Allergy & Immunology | Brain | Clinical Trials | Covid Vaccine | COVID-19 | Epidemics | Epidemiology | Immunotherapy | Intensive Care | Neurology | Stem Cell Therapy | Stem Cells | Study | Vaccines